肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展

鞠迪; 李京涛; 韩曼; 魏海梁; 闫曙光; 李汨; 史晓燕; 常占杰

doi:10.3969/j.issn.1001-5256.2018.01.042

肝星状细胞通过TGFβ1-PI3K/AKT信号通路影响肝硬化-肝细胞癌癌前病变的研究进展

DOI: 10.3969/j.issn.1001-5256.2018.01.042

1. 陕西中医药大学
2. 陕西中医药大学附属医院

基金项目:

国家自然科学基金(81603612)；陕西省科技厅(2012SF2-11,2014K11-02-04-06,2016SF-234)；陕西省中医药管理局(15-JC009,JCPT037)；北京医学奖励基金会课题(YJHYXKYJJ-276)；陕西中医药大学自然科学创新基金项目(2017SZKY-037)；

详细信息

中图分类号: R575.2;R735.7
计量
- 文章访问数: 2052
- HTML全文浏览量: 61
- PDF下载量: 394
- 被引次数: 0
出版历程
- 出版日期: 2018-01-20

Research advances in the influence of hepatic stellate cells on precancerous lesions of liver cirrhosis and hepatocellular carcinoma via the TGFβ1-PI3K/AKT signaling pathway

Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712000, China

Research funding:

摘要

摘要:
肝硬化-肝细胞癌癌前病变的恶性转变导致肝癌的形成。肝星状细胞（HSC）通过TGFβ1-PI3K/AKT信号通路影响肝细胞癌癌前病变细胞产生、肝纤维化微环境的形成以及两者相互作用。了解肝硬化-肝细胞癌癌前病变的恶变机制与HSC和TGFβ1-PI3K/AKT信号通路的关系,将有助于深入了解肝细胞癌的发生机制。通过调控HSC或干预TGFβ1-PI3K/AKT信号通路可阻止甚至或逆转肝硬化向肝细胞癌的进展,为预防和干预肝细胞癌发生提供新的思路和治疗靶点。
- 肝硬化 /
- 癌,肝细胞 /
- 癌前状态 /
- 肝星状细胞 /
- 信号传导 /
- 综述
Abstract:
The malignant transformation of the precancerous lesions of liver cirrhosis and hepatocellular carcinoma ( HCC) leads to the formation of liver cancer. Hepatic stellate cells ( HSCs) play a role in the production of cells in precancerous lesions of HCC, the formation of hepatic fibrosis microenvironment, and the interaction between them via the TGFβ1-PI3 K/AKT signaling pathway. An understanding of the mechanism for the malignant transformation of the precancerous lesions of liver cirrhosis and HCC and the association between HSCs and the TGFβ1-PI3 K/AKT signaling pathway helps to investigate the pathogenesis of HCC. Regulation of HSCs or intervention of the TGFβ1-PI3 K/AKT signaling pathway can inhibit or reverse the progression of liver cirrhosis to HCC, which provides new thoughts and therapeutic targets for prevention and intervention of the development of HCC.
- liver cirrhosis /
- carcinoma, hepatocellular /
- precancerous conditions /
- hepatic stellate cell /
- signal transduction /
- review

HTML全文

参考文献(30)

[1]VENOOK AP, PAPANDREOU C, FURUSE J, et al.The incidence and epidemiology of hepatocellular carcinoma:a global and regional perspective[J].Oncologist, 2010, 15 Suppl 4:5-13.

[2]GATENBY RA.A change of strategy in the war on cancer[J].Nature, 2009, 459 (7246) :508-509.

[3]LI Y, ZHANG Z, SHI J, et al.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBVassociated liver cirrhosis in China[J].Int J Clin Exp Med, 2015, 8 (1) :1205-1212.

[4]KEW MC.The role of cirrhosis in the etiology of hepatocellular carcinoma[J].J Gastrointest Cancer, 2014, 45 (1) :12-21.

[5]JIAO JZ, LI JT, YAN SG, et al.Current research status of precancerous dysplastic nodules in hepatocellular carcinoma[J].J Clin Hepatol, 2017, 33 (5) :974-978. (in Chinese) 焦俊喆, 李京涛, 闫曙光, 等.肝细胞癌癌前异型增生结节的研究现状[J].临床肝胆病杂志, 2017, 33 (5) :974-978.

[6]ZHANG L, ZHOU F, TEN DIJKE P.Signaling interplay between transforming growth factor-βreceptor and PI3K/AKT pathways in cancer[J].Trends Biochem Sci, 2013, 38 (12) :612-620.

[7]ZHOU Q, LUI VW, YEO W.Targeting the PI3K/Akt/m TOR pathway in hepatocellular carcinoma[J].Future Oncol, 2011, 7 (10) :1149-1167.

[8]MORMONE E, GEORGE J, NIETO N.Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches[J].Chem Biol Interact, 2011, 193 (3) :225-231.

[9]WHITTAKER S, MARAIS R, ZHU AX.The role of signaling pathways in the development and treatment of hepatocellular carcinoma[J].Oncogene, 2010, 29 (36) :4989-5005.

[10]COULOUARN C, CORLU A, GLAISE D, et al.Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma[J].Cancer Res, 2012, 72 (10) :2533-2542.

[11]SANTAMATO A, FRANSVEA E, DITURI F, et al.Hepatic stellate cells stimulate HCC cell migration via laminin-5 production[J].Clin Sci (Lond) , 2011, 121 (4) :159-168.

[12]HERNANDEZ-GEA V, TOFFANIN S, FRIEDMAN SL, et al.Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma[J].Gastroenterology, 2013, 144 (3) :512-527.

[13]THOMPSON AI, CONROY KP, HENDERSON NC.Hepatic stellate cells:central modulators of hepatic carcinogenesis[J].BMC Gastroenterol, 2015, 15:63.

[14]SONG Y, KIM SH, KIM KM, et al.Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids[J].Sci Rep, 2016, 6:36750.

[15]WANG X, HASSAN W, JABEEN Q, et al.Interdependent and independent multidimensional role of tumor microenvironment on hepatocellular carcinoma[J].Cytokine, 2017.[Epub ahead of print]

[16]TAHMASEBI BIRGANI M, CARLONI V.Tumor microenvironment, a paradigm in hepatocellular carcinoma progression and therapy[J].Int J Mol Sci, 2017, 18 (2) :405.

[17]XIA YH, LU Z, ZHAO M, et al.Tumor-specific hepatic stellate cells (t HSCs) induces DIgR2 expression in dendritic cells to inhibit T cells[J].Oncotarget, 2017, 8 (33) :55084-55093.

[18]WU K, DING J, CHEN C, et al.Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development[J].Hepatology, 2012, 56 (6) :2255-2267.

[19]KATZ LH, LI Y, CHEN JS, et al.Targeting TGF-βsignaling in cancer[J].Expert Opin Ther Targets, 2013, 17 (7) :743-760.

[20]GUPTA DK, SINGH N, SAHU DK.TGF-βmediated crosstalk between malignant hepatocyte and tumor microenvironment in hepatocellular carcinoma[J].Cancer Growth Metastasis, 2014, 7:1-8.

[21]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.Reversible human TGF-βsignal shifting between tumor suppression and fibro-carcinogenesis:implications of smad phospho-isoforms for hepatic epithelial-mesenchymal transitions[J].J Clin Med, 2016, 5 (1) .pii:E7.

[22]ZHU HB, YANG YS, GUO MZ.Transforming growth factorβ (TGF-β) and hepatocellular carcinoma[J].Chin J Gastroenterol Hepatol, 2012, 21 (3) :206-209. (in Chinese) 朱宏斌, 杨云生, 郭明洲.肝癌中转化生长因子 (TGF) -β信号转导通路的研究进展[J].胃肠病学和肝病学杂志, 2012, 21 (3) :206-209.

[23]COULOUARN C, CLEMENT B.Stellate cells and the development of liver cancer:therapeutic potential of targeting the stroma[J].J Hepatol, 2014, 60 (6) :1306-1309.

[24]YOSHIDA K, MURATA M, YAMAGUCHI T, et al.TGF-β/Smad signaling during hepatic fibro-carcinogenesis (review) [J].Int J Oncol, 2014, 45 (4) :1363-1371.

[25]ARRESE M, CABRERA D, HERNANDEZ A, et al.TGF-βand hepatocellular carcinoma:when a friend becomes an enemy[J].Curr Protein Pept Sci, 2017.[Epub ahead of print]

[26]ZHANG YE.Non-Smad pathways in TGF-beta signaling[J].Cell Res, 2009, 19 (1) :128-139.

[27]SPANGLE JM, ROBERTS TM, ZHAO JJ.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer[J].Biochim Biophys Acta, 2017, 1868 (1) :123-131.

[28]JOSHI S, SINGH AR, DURDEN DL.Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma[J].Cancer Chemother Pharmacol, 2015, 75 (3) :595-608.

[29]SINGH AR, JOSHI S, BURGOYNE AM, et al.Single agent and synergistic activity of the"first-in-class"dual PI3K/BRD4 inhibitor SF1126 with sorafenib in hepatocellular carcinoma[J].Mol Cancer Ther, 2016, 15 (11) :2553-2562.

[30]GULHATI P, BOWEN KA, LIU J, et al.m TORC1 and m TORC2 regulate EMT, motility, and metastasis of colorectal cancer via Rho A and Rac1 signaling pathways[J].Cancer Res, 2011, 71 (9) :3246-3256.

施引文献

资源附件(0)

访问统计